Clinical trials: Myocardial Infarct
Acute Coronary Disease, Angina Unstable
Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS
The purpose of this study is to evaluate whether a higher dosage of clopidogrel with aspirin (two doses) will decrease the risk of ischemic complications (cardiac death (CV death), myocardial infarction (MI), stroke) after a…
- Trial name
- CURRENT/OASIS7 (NCT00335452)
- Testing
- Clopidogrel, acetylsalicyclic acid (ASA)
- Where
- 38 sites in United States, Argentina and 36 more
- Volunteers
- 25,086 people
- Sponsor
- Sanofi
Acute Myocardial Infarction, ST Elevation MI
Nitric Oxide in Myocardial Infarction Size
The purpose of this study is to assess whether or not inhaled nitric oxide can decrease myocardial infarction (MI) size at 48-72 hours in patients presenting with an ST segment elevation MI (STEMI) who undergo successful…
- Conditions
- Acute Myocardial Infarction, ST Elevation MI, STEMI
- Trial name
- NOMI (NCT00568061)
- Testing
- Nitric Oxide
- Where
- 14 sites in United States, Belgium and 1 more
- Volunteers
- 29 people
- Sponsor
- Mallinckrodt
Coronary Artery Disease
ST Segment Detection Study
The purpose of ST Detect study is to evaluate whether naturally occurring spontaneous coronary events and exercise induced cardiac ischemia, give rise to detectable changes on intracardiac electrogram (EGM) signals in patients…
- Trial name
- ST Detect (NCT00930969)
- Testing
- ICD
- Where
- 25 sites in United States, Austria and 5 more
- Volunteers
- 175 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Myocardial Infarction
STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction
This study aims at evaluating, in a proof of concept approach, the outcome of patients presenting with acute ST-elevation myocardial infarction within 3 hours of symptom onset in either a pre-hospital setting or community…
- Trial name
- NCT00623623
- Testing
- primary PCI, enoxaparin, catheterisation
- Where
- 201 sites in Austria, Belgium and 14 more
- Volunteers
- 1,899 people
- Sponsor
- Boehringer Ingelheim
Acute Myocardial Infarction
COOL AMI EU Pivotal Trial to Assess Cooling as an Adjunctive Therapy to PCI In Patients With Acute MI (Phase A)
The objective of this trial is to evaluate the safety and effectiveness of therapeutic hypothermia, using the ZOLL Proteus IVTM System, as an adjunctive therapy for patients presenting with acute anterior myocardial infarction…
- Trial name
- NCT03173313
- Testing
- Intravascular permissive hypothermia as an adjunct to PCI
- Where
- Slovenia
- Volunteers
- 111 people
- Sponsor
- ZOLL Circulation, Inc., USA
Non-ST Elevation Myocardial Infarction (NSTEMI)
Antiplatelet Effects of Tirofiban vs. Cangrelor N-STEMI Patients Undergoing Percutaneous Coronary Intervention
Immediate potent inhibition of platelet function is critical for the prevention of periprocedural ischemic event occurrences in high risk N-ST segment elevation myocardial infarction (NSTEMI) in patients undergoing percutaneous…
- Trial name
- NCT03048019
- Testing
- Tirofiban, Cangrelor
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Inova Health Care Services
Left Ventricular Dysfunction Post Myocardial Infarction
Patient's Management Receiving Eplerenone Therapy
On a population of patients followed by an office-based cardiologist and treated with eplerenone, the objectives of the survey are: To describe the characteristics of the population treated.
- Trial name
- PERGAME (NCT01440049)
- Testing
- Prospective Observational
- Volunteers
- 160 people
- Sponsor
- Pfizer
STEMI - ST Elevation Myocardial Infarction
Cangrelor in ST-Elevation Myocardial Infarction to Decrease Infarct Size
This study evaluates differences in the extent of myocardial necrosis noted by cardiac MRI in patients with ST-elevation myocardial infarction randomized to receive cangrelor during their percutaneous coronary intervention and…
- Trial name
- NCT03043274
- Testing
- Cangrelor
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Khaled Ziada, MD
Cardiovascular Diseases, Acute Coronary Syndrome
Telemedicine in High-Risk Cardiovascular Patients Post-ACS
This is a non-CTIMP randomised controlled trial looking at the utilisation of telemedicine devices to provide remote, clinically necessary, diagnostic information, without the need for hospital attendance that patients will take…
- Trial name
- TELE-ACS (NCT05015634)
- Testing
- Active Arm, Control Arm
- Where
- United Kingdom
- Volunteers
- 337 people
- Sponsor
- Imperial College London
Myocardial Infarction, Hypercholesterolemia
Alirocumab in Patients With Acute Myocardial Infarction
Phase IV investigator initiated clinical trial to study the effectiveness of alirocumab, an inhibitor of proprotein convertase subtilisin/kexin (PCSK9), versus placebo added to high-intensity statin (atorvastatin 80 mg) in…
- Trial name
- NCT02938949
- Testing
- alirocumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Virginia Commonwealth University
ST-segment Elevation Myocardial Infarction, Non-ST-segment Elevation Myocardial Infarction
Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Acute Myocardial Infarction
The purpose of the IMPRESSION study is to determine whether intravenous administration of morphine prior to ticagrelor administration in ST-segment elevation myocardial infarction (STEMI) patients and in non-ST-segment elevation…
- Conditions
- ST-segment Elevation Myocardial Infarction, Non-ST-segment Elevation Myocardial Infarction, VA Drug Interactions
- Trial name
- IMPRESSION (NCT02217878)
- Testing
- Morphine, Ticagrelor
- Where
- Poland
- Volunteers
- 74 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Mitral Valve Insufficiency, Mitral Valve Regurgitation
EVEREST II Pivotal Study High Risk Registry (HRR)
Prospective, multi-center, single arm registry. Clinical follow-up at discharge, 30 days, 6, 12, 18 and 24, months, and 3, 4 and 5 years.
- Conditions
- Mitral Valve Insufficiency, Mitral Valve Regurgitation, Mitral Valve Incompetence, Mitral Regurgitation
- Trial name
- HRR (NCT01940120)
- Testing
- Percutaneous mitral valve repair using MitraClip implant
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- Abbott Medical Devices
Venous Thrombosis, Atrial Fibrillation
Personalized Warfarin Dosing by Genomics and Computational Intelligence
This study will create a computer program that can be used to help dose a drug called warfarin for the prevention of blood clotting.
- Conditions
- Venous Thrombosis, Atrial Fibrillation, Myocardial Infarction
- Trial name
- NCT00872079
- Testing
- Genomics
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- US Department of Veterans Affairs
Myocardial Infarction
Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI
Safety and efficacy of adjunctive antiplatelet therapy prior to primary percutaneous intervention (PCI) in patients with ST-Elevation Myocardial Infarction (STEMI)
- Trial name
- ERASE-MI (NCT00546260)
- Testing
- PRT060128 Potassium
- Where
- 31 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Coronary Arteriosclerosis, Myocardial Infarction
Culturally-Tailored Approach to Improve Medication Use in Patients With Heart Attacks
Our research aims to improve the use of medicines known to prevent recurrent heart attacks. In particular, we know that statin treatment is useful after heart attacks, but many patients do not use it.
- Trial name
- NCT00426231
- Testing
- Navigation by a health worker, Information control
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Johns Hopkins University
Coronary Artery Disease
The Dual Antiplatelet Therapy Study (DAPT Study)
The DAPT Study is a double blind randomized controlled trial intended to determine the appropriate duration for dual antiplatelet therapy (the combination of aspirin and a second anti-clotting medication) as well as the safety…
- Trial name
- NCT00977938
- Testing
- Clopidogrel & Aspirin, Prasugrel & Aspirin
- Where
- 256 sites in United States, Australia and 8 more
- Volunteers
- 25,682 people
- Sponsor
- Baim Institute for Clinical Research
Acute Myocardial Infarction
CARISMA : Cardiac Arrhythmias and Risk Stratification After MyoCardial Infarction
The purpose of this study is to assess the incidence of tachy- and bradyarrhythmic episodes in patients with acute myocardial infarction with depressed ventricular function and to determine the predictive value of several…
- Trial name
- NCT00145119
- Where
- Netherlands
- Volunteers
- 312 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Thrombocytopenia, Myocardial Infarction
Aspirin in Patients With Myocardial Infarction and Thrombocytopenia
Primary Objective: To determine the risk of bleeding from ASA therapy in thrombocytopenic patients who develop Acute Coronary Syndrome (ACS), and assess its effect on the overall morbidity and mortality in these patients as well…
- Trial name
- NCT00501345
- Testing
- Aspirin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Myocardial Infarction
Short-Term Application of Tocilizumab Following Myocardial Infarction
Introduction: Interleukin 6 (IL-6) is a cytokine that has a pro-inflammatory effect on the immune system. In acute MI IL-6 levels rapidly increase in response to ischemia and inflammation.
- Trial name
- STAT-MI (NCT02419937)
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Keesler Air Force Base Medical Center
Heart Failure, Coronary Artery Disease
A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
The purpose of this study is to assess the effectiveness and safety of rivaroxaban compared with placebo (inactive medication), in reducing the risk of death, myocardial infarction or stroke in participants with heart failure and…
- Trial name
- COMMANDER HF (NCT01877915)
- Testing
- Rivaroxaban, Standard of care for heart failure and coronary artery disease
- Where
- 562 sites in United States, Argentina and 30 more
- Volunteers
- 5,081 people
- Sponsor
- Janssen Research & Development, LLC